The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.

Abstract:

:Gestational diabetes (GD) develops because pregnancy increases requirements for insulin secretion while increasing insulin resistance. Women with GD often have impaired pancreatic beta-cell compensation for insulin resistance. The nature of GD is currently contentious, with debate about its existence, diagnosis and ramifications for both mother and offspring from pregnancy into later life. Also contentious are the outcomes of intervention with diet, insulin, glyburide (Glynase trade mark, Pharmacia Upjohn) and metformin (Glucophage trade mark, Bristol-Myers Squibb). There is consensus that women with unequivocal GD have a significant risk of adverse perinatal outcomes and increased risk of later type 2 diabetes mellitus. Foetuses from pregnancies with GD have a higher risk of macrosomia (associated with higher rate of birth injuries), asphyxia, and neonatal hypoglycaemia and hyperinsulinaemia. Uncontrolled GD predisposes foetuses to accelerated, excessive fat accumulation, insulin resistance, pancreatic exhaustion secondary to prenatal hyperglycaemia and possible higher risk of child and adult obesity and type 2 diabetes mellitus later in adult life. However, there is no consensus as to whether glucose intolerance of a severity below unequivocal GD is related to adverse maternal, fetal or perinatal outcomes, and whether this relationship is a continuous one. If dietary intervention is not sufficient in the treatment of GD, then, historically, insulin has been added. Recent studies suggest that glyburide may be efficaciously substituted for insulin. Preliminary studies suggest that metformin may have the unique potential to prevent the development of GD.

authors

Glueck CJ,Goldenberg N,Streicher P,Wang P

doi

10.1517/14656566.3.11.1557

keywords:

subject

Has Abstract

pub_date

2002-11-01 00:00:00

pages

1557-68

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

3

pub_type

杂志文章,评审
  • Glatiramer acetate for the treatment of multiple sclerosis.

    abstract::Glatiramer acetate (Copaxone, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.4.875

    authors: Wolinsky JS

    更新日期:2004-04-01 00:00:00

  • In diabetic foot infections antibiotics are to treat infection, not to heal wounds.

    abstract:INTRODUCTION:Diabetic foot ulcers, especially when they become infected, are a leading cause of morbidity and may lead to severe consequences, such as amputation. Optimal treatment of these diabetic foot problems usually requires a multidisciplinary approach, typically including wound debridement, pressure off-loading,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1021780

    authors: Abbas M,Uçkay I,Lipsky BA

    更新日期:2015-04-01 00:00:00

  • Current pharmacotherapy options for gastritis.

    abstract:INTRODUCTION:Gastritis is a broad term, which is used for different conditions by clinicians, endoscopists and pathologists. Classification strategies have led to more congruence between specialists. The histological evaluation of the gastric mucosa is mandatory for diagnosing and classifying gastritis. Main aetiologic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.747510

    authors: den Hollander WJ,Kuipers EJ

    更新日期:2012-12-01 00:00:00

  • Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?

    abstract::Alcoholism is the third leading cause of preventable mortality and morbidity in the US. In the COMBINE (Combined Pharmacotherapies and Behavioural Interventions) study, the co-primary end points were the percentage of days abstinent and the time to first heavy drinking day after 16 weeks, and 1 year. The biggest diffe...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.15.2169

    authors: Doggrell SA

    更新日期:2006-10-01 00:00:00

  • Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.

    abstract::Migraine is a multifactorial and disabling syndrome often in comorbidity with psychiatric illnesses. Triptans are the first-line treatment in acute attacks and the most effective drugs in various types of migraine. Sumatriptan was the first medication of this group. Thanks to multiple types of formulations that greatl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.858120

    authors: Napoletano F,Lionetto L,Martelletti P

    更新日期:2014-02-01 00:00:00

  • Ramipril in the treatment of vascular diseases.

    abstract::Ramipril is an angiotensin-converting enzyme inhibitor that has been extensively studied in randomised, controlled clinical trials in patients with cardiovascular diseases. Therapy with ramipril in patients with various cardiovascular disorders has demonstrated significant and clinically important reductions in cardio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.11.1911

    authors: Rokoss MJ,Teo KK

    更新日期:2005-09-01 00:00:00

  • Current concepts in the pharmacotherapy of benign prostatic hyperplasia.

    abstract::Benign prostatic hyperplasia is a major men's health issue, with approximately 80% of all men developing this condition within their lifetime. A variety of oral treatments is available, including alpha-adrenoceptor antagonists (alpha-blockers), 5alpha reductase inhibitors, aromatase inhibitors and phytotherapy. A larg...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.12.1727

    authors: Khastgir J,Arya M,Shergill IS,Kalsi JS,Minhas S,Mundy AR

    更新日期:2002-12-01 00:00:00

  • Etravirine for the treatment of HIV/AIDS.

    abstract:INTRODUCTION:Etravirine (TMC125) is an orally administered second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved in treatment-experienced patients as addition to an optimized background therapy (OBT). AREAS COVERED:A Medline search was conducted of Phase II - IV clinical trials, as ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.787411

    authors: Schrijvers R

    更新日期:2013-06-01 00:00:00

  • Evolving treatment strategies for chronic refractory angina.

    abstract::Chronic refractory angina is a term used to describe patients who, despite optimal medical therapy, have both angina and objective evidence of ischaemia. It is estimated that 5-15% of the 12 million patients with chronic angina in the US meet the criteria for having refractory angina. This review focuses on the follow...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.3.259

    authors: Yang EH,Barsness GW

    更新日期:2006-02-01 00:00:00

  • Combination strategies for pain management.

    abstract::At least two factors relating to pain management using oral analgesics suggest that combination strategies merit consideration: many pains arise from more than one physiological cause and current analgesics have adverse effect profiles that might be reduced by combination with another agent in smaller doses or with le...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.10.1697

    authors: Raffa RB,Clark-Vetri R,Tallarida RJ,Wertheimer AI

    更新日期:2003-10-01 00:00:00

  • Tamoxifen and the female reproductive tract.

    abstract::The use of tamoxifen among women with breast cancer or at high risk of the disease has greatly expanded over the past several decades. Tamoxifen has a complex effect on the female reproductive tract and several tamoxifen-associated changes have been described among tamoxifen users. These include endometrial thickening...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.9.1399

    authors: Eltabbakh GH,Mount SL

    更新日期:2001-09-01 00:00:00

  • Current therapeutical strategies for allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis is a common condition with increasing prevalence and is associated with several comorbid disorders such as bronchial asthma and atopic dermatitis. If allergen avoidance is not possible, allergen-specific immunotherapy is the only causal treatment option. AREAS COVERED:This review focuses...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1543401

    authors: Klimek L,Sperl A,Becker S,Mösges R,Tomazic PV

    更新日期:2019-01-01 00:00:00

  • Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.

    abstract::Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the b...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.11.1469

    authors: Markman M

    更新日期:2006-08-01 00:00:00

  • Recent important trials of pharmacotherapy in Parkinson's disease.

    abstract::Parkinson's disease (PD) affects approximately 1% of individuals > 60 years. Of these PD patients approximately 40% suffer dementia in later life. Levodopa is commonly used in the treatment of PD. Experimental evidence suggests that the dopamine synthesised from levodopa may contribute to the further degeneration of d...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.6.1025

    authors: Doggrell SA

    更新日期:2005-06-01 00:00:00

  • Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

    abstract:INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546346

    authors: Guan YS,He Q

    更新日期:2011-02-01 00:00:00

  • Memantine in the treatment of mild-to-moderate Alzheimer's disease.

    abstract::Memantine is the first and only medication that has been approved by European, US and Canadian regulatory agencies for the treatment of moderate-to-severe Alzheimer's disease (AD). It is an NMDA receptor antagonist that works to prevent excitotoxicity and cell death, which are mediated by the excessive influx of calci...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.2.203

    authors: Cosman KM,Boyle LL,Porsteinsson AP

    更新日期:2007-02-01 00:00:00

  • High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.

    abstract:BACKGROUND:There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent lesion formation, decrease the rate and severity of relapses and delay the resulting disability by reducing levels of inflammation. OBJECTIVE:The aim of this review was to assess the treatment o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560802677882

    authors: Hartung HP

    更新日期:2009-02-01 00:00:00

  • Current options for the management of postmenopausal osteoporosis.

    abstract:INTRODUCTION:Osteoporosis is a well-recognized disease with severe consequences if left untreated. The prevention of osteoporosis-associated fractures should include fall prevention, calcium supplementation and life-style advice, as well as pharmacological therapy using agents with proven antifracture efficacy. AREAS ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618123

    authors: Lecart MP,Reginster JY

    更新日期:2011-11-01 00:00:00

  • Emerging pharmacotherapeutic agents for insomnia: a hypnotic panacea?

    abstract::The burden of insomnia has had a significant effect not only on the socioeconomic matrix, but also the medical terrain, as signified by the increased morbidity and mortality of its associated psychiatric and organic sequelae. To this end, a plethora of pharmacotherapeutic agents have been recently introduced that addr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.13.1731

    authors: Navab P,Guilleminault C

    更新日期:2006-09-01 00:00:00

  • Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.

    abstract::HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.12.1871

    authors: del Mar Gutierrez M,Mateo G,Domingo P

    更新日期:2007-08-01 00:00:00

  • A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

    abstract:INTRODUCTION:Psoriasis is a chronic, inflammatory disease afflicting 2% of the US population; it results in significant morbidity. The annual healthcare costs related to psoriasis are an estimated $11.3 billion and, with an expanding biologic market, an updated costs analysis is needed. AREAS COVERED:Current treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.590475

    authors: Staidle JP,Dabade TS,Feldman SR

    更新日期:2011-09-01 00:00:00

  • Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.

    abstract::Selective serotonin reuptake inhibitors (SSRIs) are now generally regarded as effective and better tolerated alternatives to tricyclic antidepressants (TCAs) for the treatment of depression. SSRIs also seem to be as well tolerated as moclobemide, mirtazapine, venlafaxine, reboxetine and nefazodone and show comparable ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.5.917

    authors: Mace S,Taylor D

    更新日期:2000-07-01 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1149164

    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • Pharmacologic treatment of male breast cancer.

    abstract::Male breast cancer is an uncommon condition. It often occurs in settings in which there is an imbalance between androgens and oestrogens. Genetics plays an important role, as many cases are associated with mutations in BRCA2 or other genes. Male breast cancer occurs at an older age than female breast cancer and is fre...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903200634

    authors: Hayes TG

    更新日期:2009-10-01 00:00:00

  • Pharmacological treatment of generalized anxiety disorder.

    abstract:INTRODUCTION:Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618496

    authors: Reinhold JA,Mandos LA,Rickels K,Lohoff FW

    更新日期:2011-11-01 00:00:00

  • Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes.

    abstract::Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). Its rapid-action properties are ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.4.643

    authors: Garg SK,Ellis SL,Ulrich H

    更新日期:2005-04-01 00:00:00

  • Metabolic syndrome management.

    abstract::Overweight, obesity and the metabolic syndrome occur in genetically susceptible individuals with environmental influences, and may be further compounded by other disorders of metabolism or pharmacological therapy that increase insulin resistance or promotes weight gain. Treatment of the metabolic syndrome should focus...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2059

    authors: Stone NJ,Schmeltz LR

    更新日期:2007-09-01 00:00:00

  • Ruboxistaurin: PKC-beta inhibition for complications of diabetes.

    abstract::Diabetes mellitus is the most common cause of blindness among working-age adults, with a prevalence of 7 - 8% of adults in the USA, and is one of the most common causes of renal failure requiring kidney transplant and the most common cause of non-traumatic lower limb amputation in developed nations [1] . The role of t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903401620

    authors: Danis RP,Sheetz MJ

    更新日期:2009-12-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

    abstract::Negative symptoms are core features of schizophrenia that respond poorly to first-generation antipsychotics and present a major obstacle in rehabilitation. Patients may be somewhat more responsive to clozapine and second-generation antipsychotics but even then, considerable impairment remains. This paper reviews the u...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.10.2053

    authors: Silver H

    更新日期:2004-10-01 00:00:00